BIOCDx project is an initiative funded by the European Union under the H2020 Programme, aiming to provide a Point-of-Care (PoC) device for early cancer diagnosis and treatment monitoring.

Current diagnostic options for cancer treatment monitoring rely on imaging techniques and cannot guarantee proper assessment of therapeutic response. This project aims to develop a disruptive Point of Care (PoC) device for cancer early diagnosis and treatment monitoring as a companion diagnostics tool. One of the scientific breakthroughs of this project is the development of a “cancer stem cells” detection platform by virtue of expression of the cancer stem cell-specific transcription factor TWIST1.

BIOCDx combines advanced concepts from the photonic, nano-biochemical, micro-fluidic and reader/packaging platforms aiming to overcome limitations related to detection reliability, sensitivity, specificity, compactness and cost issues.

Project acronym: BIOCDx

Project title:  A miniature Bio-photonics Companion Diagnostics platform for reliable cancer diagnosis and treatment monitoring.

Grant agreement number:  732309

EU contribution: EUR 3 163 735

Duration: 01/01/2017 to 31/12/2019

Website: http://biocdx.eu/